Blueprint Medicines has been granted a patent for a compound that selectively inhibits MAP4K1, potentially useful in treating MAP4K1-dependent disorders, including certain cancers and viral infections. The patent outlines a method for administering this compound to affected subjects. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of June 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12042495B2 outlines a method for treating MAP4K1-dependent disorders, specifically targeting cancers and viral infections. The method involves administering an effective amount of a compound defined by a specific chemical formula to a subject in need. The patent identifies a wide range of cancers that can be treated, including but not limited to colon, pancreatic, breast, prostate, lung, ovarian, cervical, renal, bladder, stomach, liver cancers, as well as various types of leukemia, lymphoma, and melanoma. Additionally, the method is applicable to viral infections that are dependent on MAP4K1.
The claims further detail the structural characteristics of the compounds used in the treatment. These compounds may include various substituents and functional groups, such as halogens, alkyl groups, and heterocycles. Specific formulas (II, III, IV, V, VI, VII, VIII, IX, and X) are referenced, with particular attention to the selection of groups like R3, R4, and R8, which can vary in structure and composition. The patent also specifies certain conditions for the substituents, such as the presence of methyl or cyclopropyl groups, and outlines the potential for these compounds to be modified with additional functional groups. Overall, the patent presents a comprehensive approach to utilizing specific chemical compounds for the treatment of MAP4K1-dependent diseases.
To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
